The estimated Net Worth of Barry M. Deutsch is at least $969 Mille dollars as of 14 February 2020. Mr. Deutsch owns over 9,639 units of Xeris Biopharma Inc stock worth over $112,567 and over the last 6 years he sold XERS stock worth over $0. In addition, he makes $856,239 as Chief Financial Officer at Xeris Biopharma Inc.
Sign up
Mr. Deutsch XERS stock SEC Form 4 insiders trading
Barry has made over 2 trades of the Xeris Biopharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 9,639 units of XERS stock worth $40,002 on 14 February 2020.
The largest trade he's ever made was buying 9,639 units of Xeris Biopharma Inc stock on 14 February 2020 worth over $40,002. On average, Barry trades about 1,627 units every 40 days since 2018. As of 14 February 2020 he still owns at least 39,359 units of Xeris Biopharma Inc stock.
You can see the complete history of Mr. Deutsch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Barry Deutsch biography
Barry Deutsch serves as Chief Financial Officer of the Company. Mr. Deutsch joined our company in July 2017 as our vice president, business development. In April 2018, Mr. Deutsch was appointed as our Chief Financial Officer. Previously, from 2007 to 2017, Mr. Deutsch was a vice president for the BioScience Division of Baxter Healthcare Corporation, Baxalta Incorporated following its spinoff from Baxter, and Shire plc following its acquisition of Baxalta. Mr. Deutsch’s roles included serving as vice president of business development at Baxter BioScience and Baxalta and head of business development and public-private partnerships for the intercontinental region at Baxalta and Shire. Mr. Deutsch received a B.S. in Economics degree in finance and accounting from The Wharton School of the University of Pennsylvania and an M.B.A. from the Kellogg School of Management at Northwestern University.
What is the salary of Barry Deutsch?
As the Chief Financial Officer of Xeris Biopharma Inc, the total compensation of Barry Deutsch at Xeris Biopharma Inc is $856,239. There are 3 executives at Xeris Biopharma Inc getting paid more, with Paul Edick having the highest compensation of $4,307,640.
How old is Barry Deutsch?
Barry Deutsch is 57, he's been the Chief Financial Officer of Xeris Biopharma Inc since 2018. There are 9 older and 5 younger executives at Xeris Biopharma Inc. The oldest executive at Xeris Biopharma Holdings Inc is Jeffrey Sherman, 65, who is the Independent Director.
What's Barry Deutsch's mailing address?
Barry's mailing address filed with the SEC is C/O XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO, IL, 60601.
Insiders trading at Xeris Biopharma Inc
Over the last 6 years, insiders at Xeris Biopharma Inc have traded over $2,845,230 worth of Xeris Biopharma Inc stock and bought 2,912,235 units worth $31,442,123 . The most active insiders traders include Group, Llc Green Jeremy Red..., James E Deerfield Mgmt L.P.... e Garheng Kong. On average, Xeris Biopharma Inc executives and independent directors trade stock every 46 days with the average trade being worth of $197,048. The most recent stock trade was executed by John P. Schmid on 12 August 2024, trading 4,515 units of XERS stock currently worth $10,159.
What does Xeris Biopharma Inc do?
xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.
What does Xeris Biopharma Inc's logo look like?
Complete history of Mr. Deutsch stock trades at Xeris Biopharma Inc
Xeris Biopharma Inc executives and stock owners
Xeris Biopharma Inc executives and other stock owners filed with the SEC include:
-
Paul Edick,
Chairman of the Board, Chief Executive Officer -
John Shannon,
President, Chief Operating Officer -
Paul R. Edick,
Chairman & CEO -
Barry Deutsch,
Chief Financial Officer -
John P. Shannon,
Pres, COO & Director -
Beth Hecht,
Senior Vice President, General Counsel, Corporate Secretary -
Beth P. Hecht J.D.,
Sr. VP, Gen. Counsel, Corp. Sec. & Director -
John Schmid,
Lead Independent Director -
BJ Bormann,
Independent Director -
Marla Persky,
Independent Director -
Jeffrey Sherman,
Independent Director -
Dawn Halkuff,
Independent Director -
Mark Thierer,
Independent Director -
Kenneth Johnson,
Senior Vice President, Clinical Development, Regulatory, Quality Assurance and Medical Affairs -
Steven Prestrelski,
Co-Founder, Chief Scientific Officer -
Dr. Steven J. Prestrelski MBA, Ph.D.,
Co-Founder & Chief Scientific Officer -
Kevin McCulloch,
Sr. VP of Global Operations & Bus. Devel. -
Dr. Kenneth E. Johnson Pharm. D., Pharm.D.,
Sr. VP of Clinical Devel., Regulatory, Quality Assurance & Medical Affairs -
Barry M. Deutsch,
Exec. Officer -
Allison Wey,
Sr. VP of Investor Relations & Corp. Communications -
Steven M. Pieper,
Chief Financial Officer -
Dr. Steven J. Prestrelski,
Co-Founder & Chief Scientific Officer -
Group, Llc Green Jeremy Red...,
-
James E Deerfield Mgmt L.P....,
-
Partners, Ltd.Palmetto Part...,
-
Barbara Jean Anne Bormann K...,
Director -
Jonathan Rigby,
Director -
Kevin Mc Culloch,
See Remarks -
Steven Pieper,
See Remarks -
John Johnson,
Director -
Garheng Kong,
Director -
Ricki Louise Fairley,
Director